Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fate Therapeutics (FATE) Operating Leases (2019 - 2025)

Fate Therapeutics' Operating Leases history spans 7 years, with the latest figure at $73.3 million for Q4 2025.

  • For Q4 2025, Operating Leases fell 5.86% year-over-year to $73.3 million; the TTM value through Dec 2025 reached $73.3 million, down 5.86%, while the annual FY2025 figure was $73.3 million, 5.86% down from the prior year.
  • Operating Leases reached $73.3 million in Q4 2025 per FATE's latest filing, down from $74.5 million in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $109.2 million in Q4 2021 to a low of $73.3 million in Q4 2025.
  • Average Operating Leases over 5 years is $95.4 million, with a median of $99.8 million recorded in 2023.
  • Peak YoY movement for Operating Leases: soared 44.26% in 2021, then decreased 20.04% in 2024.
  • A 5-year view of Operating Leases shows it stood at $109.2 million in 2021, then decreased by 5.06% to $103.7 million in 2022, then dropped by 6.12% to $97.4 million in 2023, then fell by 20.04% to $77.8 million in 2024, then dropped by 5.86% to $73.3 million in 2025.
  • Per Business Quant, the three most recent readings for FATE's Operating Leases are $73.3 million (Q4 2025), $74.5 million (Q3 2025), and $75.7 million (Q2 2025).